Share on LinkedInShare on LinkedIn

ARTICLE · 13 FEBRUARY 2017

January 2017 Deal Round-Up

The following is a summary of major deals in the life science space that closed or were announced as closed in January 2017.

CanadaCorporate/Commercial Law

The following is a summary of major deals in the life science space that closed or were announced as closed in January 2017. Vancouver-based Quark Venture Inc., through its Global Health Sciences Venture Fund, continued to be an active investor, with investments made both in Canada and the United States in the month of January 2017.

MERGERS & ACQUISITIONS

Date: Closed January 3, 2017

Type: Amalgamation

Companies: Avagenesis Corp (TSXV: VVA) and Avapecia Life Sciences Corp. (CSE: VVS)

Deal size: Approx. CDN $12.13 million

Description: On January 3, 2017, Avapecia Life Sciences Corp. ("Avapecia") and Avagenesis Corp. ("Avagenesis") announced the completion of the transactions contemplated in their amalgamation agreement dated November 10, 2016. The amalgamated company, Liberty Biopharma Inc. ("Liberty"), will continue the business of both Avagenesis and Avapecia. Its common shares were listed on the TSX Venture Exchange under the symbol "LTY" on January

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from